Page 2 - Ongoing Phase News Today

- Initial Data from the Ongoing Phase 2 Trial in Combination with the Antibody-Drug Conjugate Sacituzumab Govitecan Suggest a Potentially Meaningful Improvement in Overall Survival for Patients...

Keros Therapeutics, Inc. announced that it presented additional data from its two ongoing Phase 2 clinical trials of KER-050, one in patients with very low-, low-, or intermediate-risk myelodysplastic...

– Safety Profile Observed to Date as Monotherapy and in Combination with Venetoclax Suggests no Overlapping Toxicity – – Initial Results from Correlative Studies Demonstrate On-target...

Phase 1 combination dose escalation expected to support planned Phase 2 trial in microsatellite stable colorectal cancer Updated Phase 1 monotherapy data for XTX101 at the recommended Phase 2 dose...

/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted TAR-200 Breakthrough Therapy Designation (BTD)...

– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the program into a pivotal Phase 3 study – – Ongoing Phase 2

– Announced topline results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the preventive treatment of episodic migraine that support advancing the...

Received FDA Agreement Under Special Protocol Assessment (SPA) for the CoMpass Phase 3 Clinical TrialPositive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial with Suprachoroidal Administration Presented at AAO 2023Preliminary Data from Phase 1 Trial in...

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial of Viaskin™ Peanut in Toddlers Viaskin Peanut showed...

Regulatory submissions on track for govorestat (AT-007) for the treatment of Classic Galactosemia to US FDA and EMA in 4Q 2023Two Upcoming Phase 3...